Centre d'Investigation Clinique du CHU de Limoges

What Centre d'Investigation Clinique du CHU de Limoges does

Centre d'Investigation Clinique du CHU de Limoges (CIC 1435) is a non-profit, multi-thematic clinical investigation center embedded within CHU de Limoges, a French public university hospital, operating under Inserm certification since 2008. The center coordinates Phase 1–4 clinical trials across four thematic axes — Infectiology, Pharmacology, Immuno-Hematology, and Ultrasound diagnostics — with sepsis as the unifying backbone, and manages 278 ongoing studies with 54 new setups and 4,227 patients included in 2024. Its core technology stack combines a translational research platform interfacing Inserm and CNRS fundamental units with clinical services, an ISO 20387-certified Biological Resources Center housing the SELPSIS septic-patient stool collection and healthy-volunteer biorepository, and a 20-year specialized program in ventilator-associated pneumonia with monoclonal antibody research across 16 European centers.

The organization operates through four linked service units: the parent CIC providing core investigation services; ARCH (created 2012) extending clinical research support to non-university hospitals, private clinics, and the GENERALIM primary-care network via a territorial portal and mobile investigation team; INCREASE (created 2013) coordinating European and national consortium projects; and MUST (created 2017) delivering independent external monitoring for sepsis trials. Revenue is generated through three streams: institutional funding from Inserm and CHU de Limoges, competitive grants from national (ANR, Bpifrance, INCa) and European (Horizon 2020, IMI, ECRAID-Base) programs, and fee-for-service industrial partnership agreements with pharmaceutical and biotech sponsors.

CIC 1435 is governed as a public-sector entity with no venture or private-equity backing; control rests with CHU de Limoges administration and Inserm oversight through periodic re-labelling (most recently renewed by Hcéres in 2023, valid through 2027). The center holds ISO 9001:2015 certification (since 2021, scope extended to teaching in 2024) and ISO 20387 certification for its biobank (since 2023). Its competitive position rests on regulatory credentials, a specialized sepsis/ICU talent base, and deep integration with pan-European research networks including ECRAID, COMBACTE-NET/MAGNET/CARE, CRICS-TRIGGERSEP, I-REIVAC, and PROMISE, combined with academic partnerships to the Université de Limoges and joint DIU training programs with Tours, Rouen, and Bordeaux.

Name

Centre d'Investigation Clinique du CHU de Limoges

Legal name

Centre d'Investigation Clinique du Centre Hospitalier Universitaire de Limoges

Website

https://cic.chu-limoges.fr

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

11–50 employees

Short description

CIC 1435 is a non-profit Inserm-certified clinical investigation center at CHU de Limoges, France, conducting Phase 1–4 trials in infectiology, pharmacology, immuno-hematology, and ultrasound — with sepsis as its backbone — for academic and pharmaceutical sponsors across European multicenter networks.

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Other Scientific and Technical Consulting Services (54169), Medical Laboratories (621511)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Data Management, Reporting & Regulatory Submissions for Central Labs (HLAGAEAL)

akta.pro secondary industry

Clinical Research Support (CRC/CTA) (EDAOAJAO)

Keywords

• Clinical investigation services
• Clinical trial coordination
• Translational medical research
• Sepsis clinical research
• Biological resource center

Headquarters

HQ city

Limoges

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Others

Revenue model

1. Institutional Funding: Core funding from Inserm and CHU de Limoges to maintain clinical research infrastructure, personnel, and operations.
2. Competitive Research Grants: Project-based funding from national agencies (ANR, Bpifrance, INCa) and European programs (Horizon 2020, IMI, ECRD-Base) for specific research projects and clinical trials.
3. Industrial Partnership Agreements: Fee-for-service contracts with pharmaceutical and biotech companies for clinical trial coordination, monitoring, and investigation support services. Balances maintained between industrial and institutional research for self-funding and scientific output.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

CIC 1435 is a multi-thematic clinical investigation center that designs, coordinates, and conducts phase 1–3 clinical trials and translational studies for academic and industrial sponsors in infectious diseases, pharmacology, immuno-hematology, and ultrasound. It provides end-to-end services including study setup, regulatory submissions, patient and healthy volunteer recruitment, investigation, monitoring, data management, sample management (CRB), and publication support, with a particular focus on sepsis and ventilator-associated pneumonia research.

Product overview

Centre d'Investigation Clinique du CHU de Limoges (CIC 1435) is a multi-thematic clinical investigation center providing comprehensive clinical research services. The organization operates as a unified service structure comprising core clinical investigation capabilities alongside specialized units: ARCH for hospital clinical research support including mobile teams and territorial portal activities; INCREASE for European and national project coordination; MUST for sepsis trial monitoring services; CRB for biological sample collections; and structured training programs. The center focuses its research on four thematic axes—Infectious Diseases, Pharmacology, Immuno-Hematology, and Ultrasound—with Sepsis as the common backbone, and maintains ISO 9001:2015 certification for investigation activities and teaching.

Differentiator

Problem solved

Functional benefit

Brands

• ARCH: Accompagnement de la Recherche Clinique Hospitalière - Hospital Clinical Research Support structure providing investigation support within CHU de Limoges and at the extra-hospitalary level
• INCREASE
• MUST

Products and services

• CIC 1435 Multi-Thematic Clinical Investigation Center Services
• ARCH - Hospital Clinical Research Support
• INCREASE - European and National Project Coordination
• MUST - Monitoring Unit for Sepsis Trials
• CRB - Biological Resources Center
• Clinical Research Training Programs
• Healthy Volunteer Research Program

Quantifiable outcome

• 54 studies set up in 2024, 278 ongoing studies, 4,227 patients included in 2024
• +2 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

15 partnerships are on record, tiered core and minor.

• ECRAID (European Clinical Research Alliance on Infectious Diseases)coreStrategic or Co-development Partner · 1 January 2021European clinical research alliance developing research in infectious diseases by coordinating the largest permanent autonomous university-led clinical research network in Europe. Created by ECRAID-Base project funded by EU (2021-2026). CIC 1435 participates through INCREASE structure.
• EU-JAMRAI (European Joint Action on Antimicrobial Resistance)minorStrategic or Co-development Partner · 1 January 2017European Joint Action on antimicrobial resistance and healthcare-associated infections coordinated by Inserm, bringing together 44 partners from 27 countries with One Health dimension.
• COMBACTE-MAGNETcoreStrategic or Co-development Partner · 1 January 2015Combatting Bacterial Resistance in Europe - Molecules Against Gram-Negative Infections. Objectives include understanding causes of infections due to antibiotic-resistant Gram-negative bacteria, particularly respiratory infections.
• COMBACTE-CAREcoreStrategic or Co-development Partner · 1 January 2015Combatting Resistance in Europe - Carbapenem Resistance. Consortium targeting carbapenem-resistant bacterial infections with objectives to understand resistance mechanisms for better patient treatment.
• SEPCELLminorStrategic or Co-development Partner · 1 January 2015H2020 project developing mesenchymal stem cell therapy for severe sepsis patients, with adipose-derived stem cells administered in clinical trial.
• COMBACTE-NETcoreStrategic or Co-development Partner · 1 January 2013First COMBACTE consortium creating three essential pillars: CLIN-Net (European investigation site network), LAB-Net (laboratory network), and STAT-Net (statistics network), dedicated to antibiotic resistance research.
• CRICS-TRIGGERSEP (Clinical Research in Intensive Care and Sepsis)coreStrategic or Co-development PartnerF-CRIN network focused on personalized medicine in sepsis, developing and supporting new therapeutic approaches through multicenter trials, biomarker identification, and exploration of therapeutic targets.
• I-REIVACcoreStrategic or Co-development PartnerNational clinical investigation network in vaccinology bringing together 18 centers including 7 CICs, 2 Clinical Research Centers, immunology services and laboratories, coordinated by AP-HP Cochin.
• PROMISEcoreStrategic or Co-development PartnerPriority Research Program against antibiotic resistance launched November 2021, bringing together 79 partners in a One Health meta-network (human, animal, and environmental health).
• CLIN-Net FrancecoreStrategic or Co-development PartnerFrench branch of European CLIN-Net coordinated by INCREASE unit, federating infectious disease investigation networks (RENARCI, OUTCOME REA) and isolated investigators, with dedicated IT platform for ICU services.
• UMR Inserm 1092 (RESINFIT)coreTechnology or IntegrationResearch collaboration on microbiology and resistance mechanisms, including cytomegalovirus resistance dynamics and antiviral resistance (hepatitis B and C).
• UMR Inserm 1248 (Pharmacology)coreTechnology or IntegrationCollaboration on immunosuppressant pharmacology in transplantation, pharmacogenetics, pharmacokinetics, proteomics, and antiviral therapeutic individualization.
• UMR CNRS 7276 (Immuno-hematology)coreTechnology or IntegrationCollaboration on immuno-hematology including early biotherapy trials, lymphoma research (elderly, marginal zone, NK/T), and immunoglobulin deposition diseases.
• FILFOIE (Filière de Santé Maladies Rares)minorChannel Partner/ Reseller/ DistributorRare diseases network providing clinical research support and coordination for specialized disease areas.
• Université de Limoges - Faculties of Medicine and PharmacycoreStrategic or Co-development PartnerAcademic partnership for training in clinical research, joint DIU programs, and student internships.

Scale indicators10 records

Recent moves13 records

Expansion highlights6 records

Broad incumbents

• Duke Clinical Research Institute: Academic clinical research organization at Duke University conducting large-scale trials across cardiovascular, infectious disease, and other therapeutic areas. Comparable mission and CRO-like operating model, though at materially larger scale with global pharma partnerships.
• ECRIN (European Clinical Research Infrastructure Network): Pan-European non-profit infrastructure supporting multinational clinical trial coordination across disease areas. Comparable in mission (academic clinical trial coordination) but operates at continental scale rather than single-site, positioning it as both a peer and a potential strategic partner/umbrella for CIC 1435.

Regional players

• INCA (Institut National du Cancer): French national cancer agency funding and coordinating oncology research. Peer in the French clinical research ecosystem and a source of competitive grant funding for CIC 1435's oncology-related work, though focused exclusively on cancer rather than the center's multi-thematic mandate.
• EORTC (European Organisation for Research and Treatment of Cancer): Pan-European non-profit organization conducting cancer clinical trials across multiple member institutions. Comparable academic clinical research network structure and EU-funded operating model, though focused exclusively on oncology rather than the multi-thematic scope of CIC 1435.

Direct peers

• Oxford Clinical Trials Research Unit (OCTRU): University of Oxford-based clinical trials unit conducting randomized trials across multiple therapeutic areas with academic and industry sponsorship. Comparable as an academic clinical trial coordination unit with similar funding mix and methodological focus.
• CIC de Lyon (HCL): Inserm-labeled CIC at Hospices Civils de Lyon, providing the same multi-thematic clinical investigation services model as CIC 1435. Direct peer in terms of structural setup, Inserm certification cycle, and clinical trial coordination mandate.
• CIC Pitié-Salpêtrière (AP-HP): Another Inserm-labeled multi-thematic Centre d'Investigation Clinique within a major French university hospital (AP-HP). Directly comparable as a French CIC providing Phase 1-3 clinical investigation services, though based in Paris with broader therapeutic scope.
• CIC de Bordeaux: Inserm-labeled CIC at CHU de Bordeaux, structurally identical to CIC 1435 as a multi-thematic clinical investigation center within a French university hospital. Offers comparable Phase 1 healthy volunteer and hospitalized patient trial capabilities.
• Charité Research Organisation GmbH: Academic clinical research organization affiliated with Charité – Universitätsmedizin Berlin, providing Phase 1-4 trial coordination, monitoring, and project management. Directly comparable as a European academic CRO embedded in a university hospital, with similar sponsor mix of public grants and industry contracts.
• CTU Bern (University of Bern): Clinical Trials Unit at the University of Bern coordinating academic and industry-sponsored trials with similar methodological, monitoring, and project management services. Comparable European academic CRO with multi-disease scope and similar translational research mandate.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/centre-d-investigation-clinique-du-chu-de-limoges

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Centre d'Investigation Clinique du CHU de Limoges